Will Rousmaniere

Direttore Finanziario/CFO presso ANALOGIC CORPORATION

Health Technology

Consumer Services

Electronic Technology

Profilo

William Rousmaniere is currently the Chief Financial Officer, Secretary & Treasurer at Analogic Corp.
and Lundbeck Seattle BioPharmaceuticals, Inc. He previously worked as the Director-Finance, Precision Motion & Technologies at Novanta, Inc. Mr. Rousmaniere completed his undergraduate degree at Cornell University and holds an MBA from The Leonard N Stern School of Business.

Posizioni attive di Will Rousmaniere

Società	Posizione	Inizio
ANALOGIC CORPORATION	Direttore Finanziario/CFO	22/06/2018
ALDER BIOPHARMACEUTICALS, INC.	Direttore Finanziario/CFO	-

Tutte le posizioni attive di Will Rousmaniere

Precedenti posizioni note di Will Rousmaniere

Società	Posizione	Fine
NOVANTA INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Will Rousmaniere

Formazione di Will Rousmaniere

The Leonard N Stern School of Business	Masters Business Admin
Cornell University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Will Rousmaniere

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
NOVANTA INC.	Electronic Technology

Aziende private	2
Analogic Corp. Analogic Corp. Medical SpecialtiesHealth Technology Analogic Corp. engages in the business of designing, development manufacturing, and supporting technically advanced and cost-effective imaging and detection, and power and automation solutions for security, healthcare, and other high-end industrial markets. The firm is also involved in the innovation in the field of computed tomography. The company was founded by Bernard Marshall Gordon on November 27, 1967 and is headquartered in Peabody, MA.	Health Technology
Lundbeck Seattle BioPharmaceuticals, Inc. Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.	Health Technology

Aziende private